OVID

Ovid Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 7/10
  • Value↓ 0/10
Ovid Therapeutics sales and earnings growth
OVID Growth
Good
  • Revenue Y/Y↑ 1181.27%
  • EPS Y/Y↑ 37.84%
  • FCF Y/Y↑ 31.58%
Ovid Therapeutics gross and profit margin trends
OVID Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -240.10%
  • ROIC 5Y↓ -42.44%
Ovid Therapeutics net debt vs free cash flow
OVID Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Ovid Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗